Neurocrine Biosciences (NBIX)
NASDAQ:NBIX
Want to see NBIX full AI Analyst Report?
NBIX Stock Chart & Stats
$133.25
$0.29(0.21%)
At close: 4:00 PM EST
$133.25
$0.29(0.21%)
Day’s Range― - ―
52-Week Range$122.14 - $162.39
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.26M
Market Cap
$15.92B
Enterprise Value$16.06B
Total Cash (Recent Filing)$1.32B
Total Debt (Recent Filing)$406.20M
Price to Earnings (P/E)24.2
Beta0.69
Next Earnings
Aug 04, 2026EPS Estimate
1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.71
Shares Outstanding100,549,980
10 Day Avg. Volume1,145,510
30 Day Avg. Volume1,257,044
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)4.34
Price to Sales (P/S)4.93
P/FCF Ratio18.85
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.18
Enterprise Value/Gross Profit5.27
Enterprise Value/Ebitda18.22
Forecast
1Y Price Target
$188.76Price Target Upside41.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)7.61
Revenue Forecast (FY)$3.70B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthSustained FCF near $831M and ~96% conversion of earnings signals high earnings quality and strong internal funding. This durable cash generation supports R&D, commercial scale‑up, and acquisitions without heavy reliance on external financing, strengthening strategic optionality over months.
High Margins & ProfitabilityVery high gross and expanding operating margins reflect a capital-light commercial model driven by proprietary medicines and pricing power. Margin durability underpins reinvestment capacity for trials and launches and provides resilience to cost variability across the medium term.
Robust R&D Pipeline MomentumA broad, active pipeline with numerous early starts and upcoming Phase 3 readouts diversifies future value drivers beyond core products. Persistent clinical activity and gene‑therapy advancement increase long‑term upside potential and reduce reliance on any single commercial asset over 2–3 years.
Bears Say
Acquisition Financing & CovenantsThe $2.9B Soleno close and $600M draw on a secured $1B revolver materially increase near‑term leverage and introduce covenant constraints. This can limit financial flexibility, raise interest exposure, and pressure FCF or capital allocation while integration and launch investments are absorbed.
Revenue ConcentrationHeavy dependence on INGREZZA for core sales concentrates commercial risk: payer coverage changes, reauthorization seasonality, or demand shifts could materially affect revenue. New launches must scale to meaningfully diversify sales, leaving near‑term earnings exposed to single‑product dynamics.
Early Commercial Penetration Risk (Cranesity)Cranesity shows promising early metrics but low penetration and limited prescriber experience indicate execution risk. Scaling adoption may require sustained marketing and payer engagement; slower conversion could necessitate higher commercial spend and compress near‑term margins and returns.
Neurocrine News
NBIX FAQ
What was Neurocrine Biosciences’s price range in the past 12 months?
Neurocrine Biosciences lowest stock price was $122.14 and its highest was $162.39 in the past 12 months.
What is Neurocrine Biosciences’s market cap?
Neurocrine Biosciences’s market cap is $15.92B.
When is Neurocrine Biosciences’s upcoming earnings report date?
Neurocrine Biosciences’s upcoming earnings report date is Aug 04, 2026 which is in 62 days.
How were Neurocrine Biosciences’s earnings last quarter?
Neurocrine Biosciences released its earnings results on May 05, 2026. The company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.216 by $0.694.
Is Neurocrine Biosciences overvalued?
According to Wall Street analysts Neurocrine Biosciences’s price is currently Undervalued.
Does Neurocrine Biosciences pay dividends?
Neurocrine Biosciences does not currently pay dividends.
What is Neurocrine Biosciences’s EPS estimate?
Neurocrine Biosciences’s EPS estimate is 1.56.
How many shares outstanding does Neurocrine Biosciences have?
Neurocrine Biosciences has 100,549,980 shares outstanding.
What happened to Neurocrine Biosciences’s price movement after its last earnings report?
Neurocrine Biosciences reported an EPS of $1.91 in its last earnings report, beating expectations of $1.216. Following the earnings report the stock price went up 8.855%.
Which hedge fund is a major shareholder of Neurocrine Biosciences?
Currently, no hedge funds are holding shares in NBIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$188.76 (41.66% Upside)
$188.76 (41.66% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.87%
12-Months-Change
Fundamentals
Return on Equity
21.64%
Trailing 12-Months
Asset Growth
33.04%
Trailing 12-Months
Company Description
Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX Company Deck
NBIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial performance (record quarterly net product sales, INGREZZA growth of 20% YoY to $657M, Cranesity annualizing >$600M, ~44% overall revenue growth) alongside robust pipeline progress (multiple Phase 1/2 starts in 2026 and key Phase 3 readouts expected in 2027). Minor near-term headwinds were noted, including Q1 gross-to-net pressure for Cranesity, recurring Q1 payer seasonality for INGREZZA, early-stage commercial penetration for Cranesity, and limited disclosure on an in-progress acquisition. Overall, the positive commercial execution, high profitability, and strong R&D momentum materially outweigh the modest operational and timing risks discussed on the call.View all NBIX earnings summariesNBIX Stock 12 Month Forecast
Average Price Target
$188.76
▲(41.66% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
Amphastar Pharmaceuticals
―
Ownership Overview
1.15% Insiders
26.37% Mutual Funds
21.81% Other Institutional Investors
21.18% Public Companies and
Individual Investors